Updated results of the SOFT study: A randomized phase III trial of S-1/oxaliplatin (SOX) plus bevacizumab versus 5-FU/I-LV/oxaliplatin (mFOLFOX6) plus bevacizumab in patients with metastatic colorectal cancer (mCRC).

被引：1

作者：

Nakamura, Masato

Yamada, Yasuhide

Takahari, Daisuke

Matsumoto, Hiroshi

Baba, Hideo

Yoshida, Kazuhiro

Yoshida, Motoki

Iwamoto, Shigeyoshi

Shimada, Ken

Komatsu, Yoshito

Sasaki, Yasutsuna

Satoh, Taroh

Takahashi, Keiichi

Mishima, Hideyuki

Muro, Kei

Watanabe, Masahiko

Sakata, Yuh

Morita, Satoshi

Shimada, Yasuhiro

Sugihara, Kenichi

机构：

[1] Aizawa Hosp, Matsumoto, Nagano, Japan

[2] Natl Canc Ctr, Gastrointestinal Med Oncol Div, Tokyo, Japan

[3] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi 464, Japan

[4] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Tokyo, Japan

[5] Kumamoto Univ, Kumamoto, Japan

[6] Gifu Univ, Sch Med, Dept Surg Oncol, Gifu 500, Japan

[7] Osaka Med Coll Hosp, Ctr Canc Chemotherapy, Osaka, Japan

[8] Kansai Med Univ, Takji Hosp, Dept Surg, Moriguchi, Osaka 570, Japan

[9] Saitama Med Univ, Hidaka, Japan

[10] Hokkaido Univ Hosp, Dept Canc Ctr, Sapporo, Hokkaido 060, Japan

[11] Showa Univ, Tokyo, Japan

[12] Osaka Univ, Osaka, Japan

[13] Komagome Hosp, Dept Surg, Tokyo Metropolitan Canc, Tokyo, Japan

[14] Komagome Hosp, Ctr Infect Dis, Tokyo, Japan

[15] Aichi Med Univ, Unit Canc Ctr, Nagakute, Aichi 48011, Japan

[16] Kitasato Univ, Sch Med, Sagamihara, Kanagawa 228, Japan

[17] Misawa City Hosp, Misawa, Japan

[18] Kyoto Univ, Grad Sch Med, Dept Biomed Stat & Bioinformat, Kyoto, Japan

[19] Tokyo Med & Dent Univ, Grad Sch, Dept Surg Oncol, Tokyo, Japan

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期

关键词：

D O I：

10.1200/jco.2014.32.15_suppl.3586

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3586

引用

页数：1

共 50 条

[31] SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer, (vol 34, pg 1723, 2016)
van Hazel
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (33) : 4059 - 4059
[32] Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial (vol 14, pg 1278, 2013)
Yamada, Y.
Takahari, D.
Matsumoto, H.
LANCET ONCOLOGY, 2014, 15 (01): : E4 - E4
[33] A phase II study of 5-FU/1-LV/oxaliplatin (mFOLFOX6) in patients with metastatic or unresectable small bowel adenocarcinoma.
Nakayama, Norisuke
Horimatsu, Takahiro
Takagi, Seiichi
Moriwaki, Toshikazu
Hirashima, Yoshinori
Fujita, Mikio
Asayama, Masako
Moriyama, Ichiro
Nakashima, Koji
Baba, Eishi
Kitamura, Hiroshi
Tamura, Takao
Hosokawa, Ayumu
Muto, Manabu
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[34] S-1/oxaliplatin (SOX) plus bevacizumab (Bev) as first line followed by S-1/irinotecan (IRIS) plus cetuximab (Cmab) as second line therapy in metastatic colorectal cancer (mCRC) (SOBIC trial)
Nakamoto, Y.
Mikami, R.
Umeki, M.
Tokunaga, Y.
Okumoto, T.
Kawamura, T.
Fujiwara, H.
Doi, S.
Noda, M.
Tomita, N.
ANNALS OF ONCOLOGY, 2017, 28 : 44 - 44
[35] PRESPECIFIED SUBGROUP ANALYSES IN WJOG4407G TRIAL, A RANDOMIZED PHASE III TRIAL OF MFOLFOX6 PLUS BEVACIZUMAB VERSUS FOLFIRI PLUS BEVACIZUMAB IN FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER
Hiroshi, Tamagawa
Kentaro, Yamazaki
Koichi, Suyama
Michio, Okabe
Kazuya, Suzuki
Nobuhiko, Seki
Kentaro, Kawakami
Mikio, Sato
Yasuo, Takahashi
Tomonori, Hirashima
Masahide, Ebi
Keisei, Taku
Toshio, Otsuji
Fumio, Tamura
Eiji, Shinozaki
Koji, Nakashima
Kensei, Yamaguchi
Masahiko, Ando
Satoshi, Morita
Narikazu, Boku
Ichinosuke, Hyodo
ANNALS OF ONCOLOGY, 2014, 25
[36] A randomized phase III study of sox (S-1/oxaliplatin) versus COX (capecitabine/oxaliplatin) in patients with advanced colorectal cancer
Park, Y. S.
Lim, H. Y.
Lee, J.
Kim, T. W.
Lee, J.
Hong, Y. S.
Kim, S. Y.
Baek, J. Y.
Kim, J. H.
Lee, K.
Chung, I.
Cho, S.
Lee, K. H.
Shin, S. J.
Kang, H. J.
Shin, D.
Jo, S. J.
Lee, J. W.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[37] Impact of sex on the efficacy of first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus Y90-radioembolization in patients with metastatic colorectal cancer: An exploratory, retrospective analysis of the phase III SIRFLOX trial
Heinrich, Kathrin
Heinemann, Volker
Westphalen, Benedikt
Oecal, Osman
Van Hazel, Guy A.
Gibbs, Peter
Seidensticker, Max
Ricke, Jens
Seidensticker, Ricarda
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[38] Final results of phase II study of S-1, oral leucovorin, oxaliplatin, and bevacizumab combination therapy (SOL plus BV; SOLA) in metastatic colorectal cancer (mCRC).
Yamazaki, Kentaro
Nishina, Tomohiro
Kato, Takeshi
Yoshino, Takayuki
Miyata, Yoshinori
Esaki, Taito
Moriwaki, Toshikazu
Boku, Narikazu
Hyodo, Ichinosuke
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
[39] A randomized phase III clinical trial of sequential capecitabine or 5-FU plus bevacizumab (Cape/5-FU+Bmab) followed by Cape/5-FU plus oxaliplatin plus Bmab (CapeOX/mFOLFOX6+Bmab) versus combination CapeOX/mFOLFOX6+Bmab in advanced colorectal cancer: The C-cubed (C3) study.
Ojima, Hitoshi
Mishima, Hideyuki
Sawaki, Akira
Nagasaka, Takeshi
Shimokawa, Mototsugu
Inukai, Michio
Shinozaki, Katsunori
Tanioka, Hiroaki
Nasu, Junichiro
Nishina, Tomohiro
Hazama, Shoichi
Okajima, Masazumi
Tsuji, Akihito
Tsuji, Yasushi
Munemoto, Yoshinori
Yamaguchi, Shigeki
Yamaguchi, Yoshiyuki
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
[40] PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer
Schwartzberg, Lee S.
Rivera, Fernando
Karthaus, Meinolf
Fasola, Gianpiero
Canon, Jean-Luc
Hecht, J. Randolph
Yu, Hua
Oliner, Kelly S.
Go, William Y.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (21) : 2240 - +

← 1 2 3 4 5 →